You just read:

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

News provided by

Novartis Pharmaceuticals Corporation

Jul 18, 2018, 12:59 ET